your market intelligence analyst
Search Results
95 results
Your search is now limited to «Clinical Trials» expert search.
Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes.
More from Healthcare Sales & Marketing Network:
Business Wire 07/30/2020 06:24
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes.
More from Business Wire:
GlobeNewswire 07/28/2020 08:30
The company’s pivotal GRACE trial is enrolling 130 patients with all etiologies of Cushing’s syndrome at sites in the United States, Canada, Europe and Israel.
More from GlobeNewswire:
Benzinga 07/27/2020 07:00
DalCor would like to thank all the patients, investigators, and study sites for their continued participation in the dal-GenE study.
More from Benzinga: 07/23/2020 07:28
Condition : Pulmonary Arterial Hypertension Interventions : Drug: TPN171H; Drug: Placebo; Drug: Tadalafil Sponsors : Vigonvita Life Sciences; Shanghai Institute of Materia Medica, Chinese Academy of Sciences Not yet recruiting.
More from
Results from the Phase III THALES trial confirm that aspirin plus Brilinta has the potential to be a new effective treatment option for these high-risk patients and we look forward to continuing discussions with regulatory authorities.
More from Pharmaceutical Business Review:
PharmaTimes 07/16/2020 03:52
AstraZeneca has now shared detailed results from the Phase III THALES, showing that a combination of twice daily Brilinta (ticagrelor) and daily aspirin reduced the rate of stroke and death (the composite primary endpoint) by 17% after 30 days compared to aspirin alone in patients ...
More from PharmaTimes: 07/09/2020 17:07
The finerenone Phase III clinical program is comprised of two studies which randomized more than 13,000 patients with CKD and T2D from around the world to evaluate the effect of finerenone versus placebo on top of standard of care ...
More from
Seeking Alpha 07/07/2020 14:33
Treatment of stroke patients with the sig1R agonist cutamesine in a phase 2 trial improved motor scores.
More from Seeking Alpha:
PR Newswire 06/29/2020 12:00
In addition to its current Phase 2 cardiovascular clinical program, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function ...
More from PR Newswire:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications